Semaglutide and Dapagliflozin for Glucose and Weight Management in Type 1 Diabetes
Triple therapy for T1DM with insulin, semaglutide and dapagliflozin
We are looking for adults with type 1 diabetes for a research study. The purpose of the study is to see how well an already approved treatment for type 2 diabetes works for people with type 1 diabetes.
You will be in this study for just over a year (55 weeks). During that time, you will have 16 study visits that will last from 45-60 mins (most visits) to 5 hours (a few visits). You will take either your current diabetes treatment or the study drug. You will also complete urine tests, blood draws, and questionnaires. Study visits will take place at 1000 Youngs Rd.,Williamsville, NY 14221.
Participants will be compensated.
This will be an interventional project to study the glycemic effect of the addition of a GLP-1 RA (semaglutide) and an SGLT-2 inhibitor (dapagliflozin) as adjunct therapies to insulin treatment in adult type 1 diabetes patients
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Adults ages 18+.
Diagnosed with Type 1 diabetes.
Currently using an insulin pump or multiple daily injections of insulin.
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the
contact information above or email firstname.lastname@example.org and someone will assist you.
Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality
assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided
in the aforementioned ways, please contact email@example.com.